LCTX Lineage Corp Long-Term Loans to Capital Ratio
Lineage Cell Therapeutics (LCTX) holds a high status in the field of tissue regeneration, yet the absence of profitable products creates a financial dependence on external grants. The price indicator on this chart reflects the asset's dynamics, with a metric of 0.02. Company management is focused on developing cell-based methods to combat vision loss and expanding the functionality of its technological base.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_LCTX_-_Lineage-Cell-Therapeutics_-_Long-Term-Debt-to-Capital "Lineage Cell Therapeutics, Inc. - LCTX Long-Term Liabilities to Capital (period 07/04/2022 - 10/29/2026) | 👁️GURU.Markets👁️")
Lineage Cell Therapeutics (LCTX) - metric breakdowns and financial figures
By developing a cell therapy platform to combat neurological and ophthalmological pathologies, Lineage Cell Therapeutics (LCTX) diversifies risk through a broad research portfolio. The current value of 0.02 reflects the ratio of long-term loans to the market value of equity, allowing investors to assess financial leverage and the stability of the capital structure regarding long-term liabilities relative to the company's equity.